Alzheon Inc.
Quick facts
Phase 3 pipeline
- Experimental: ALZ-801 · Neurology
ALZ-801 is a small-molecule inhibitor of tau protein aggregation that crosses the blood-brain barrier to reduce pathological tau accumulation in the brain.
Phase 2 pipeline
- ALZ-801 · Neurology
ALZ-801 is a dual A beta 42 and A beta 40 inhibitor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: